Talecris Biotherapeutics' $4 billion takeover by Grifols SA of Spain has won tentative approval from U.S. antitrust regulators, after the companies agreed to sell some assets.
Company officials have been in negotiations for months with the U.S. Federal Trade Commission, which wants to ensure the deal doesn't lead to higher prices for specialized drugs made from blood plasma.
Under a consent agreement with the FTC announced this morning, the companies agreed to sell Talecris' plant in Melville, N.Y., a division that makes a plasma-derived drug to treat hemophilia and two plasma collection centers.
The deal, first announced in June, creates a new corporate parent for Talecris, North Carolina's largest biotechnology company. Based in Research Triangle Park, Talecris employs more than 2,200 people in the Triangle, mostly at a massive drug factory in Clayton.